TNFSF15抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Mouse kidney tissue, Primary antibody: P12310(TNFSF15 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12310(TNFSF15 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12310(TNFSF15 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of TNFSF15 Antibody**

TNFSF15 (tumor necrosis factor superfamily member 15), also known as TL1A, is a cytokine encoded by the *TNFSF15* gene. It binds to the death domain receptor DR3 (TNFRSF25) and the decoy receptor DcR3 (TNFRSF6B), playing a critical role in modulating immune responses, particularly in inflammatory and autoimmune diseases. TNFSF15 is expressed by endothelial cells, monocytes, and lymphocytes, and its signaling promotes pro-inflammatory pathways, including T-cell activation, cytokine production, and angiogenesis.

Dysregulation of TNFSF15 has been implicated in pathologies such as inflammatory bowel disease (IBD), rheumatoid arthritis, and certain cancers. Elevated TNFSF15 levels correlate with disease severity in IBD, suggesting its role as a therapeutic target. TNFSF15 antibodies are designed to neutralize this cytokine, thereby inhibiting DR3-mediated signaling and attenuating excessive inflammation.

Preclinical and clinical studies have explored anti-TNFSF15 antibodies for treating IBD, demonstrating potential in reducing intestinal inflammation and mucosal damage. Challenges include optimizing specificity to avoid interference with homeostatic immune functions and addressing the dual-receptor interaction (DR3 vs. DcR3). Current research also investigates combination therapies and biomarkers to predict patient responsiveness.

Overall, TNFSF15 antibodies represent a promising therapeutic strategy for immune-mediated disorders, with ongoing efforts focused on enhancing efficacy and safety profiles.